TheraRadar
Data updated: May 26, 2026

ELEVIDYS (delandistrogene moxeparvovec-rokl)

Approved 2023-06-21
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2023-06-21
Patent Cliff
2035
Revenue
$402M (FY-2025)

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
Intravenous
Dosage Forms
Suspension

Companies

Sarepta Therapeutics
Active Ingredient: delandistrogene moxeparvovec-rokl

ELEVIDYS Approval History

2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2023 to 2023
Jun 2023 ORIGINAL
Update · CBER biologic (Purple Book)

What ELEVIDYS Treats

1 FDA approvals

Originally approved for its first indication in 2023 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT07542314 ENHANCE SRP-9001-402 Ph 4 not yet recruiting Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ELEVIDYS FDA Label Details

Pro Intelligence Preview

Deep insights for ELEVIDYS

Revenue Insights

  • • FY-2025: $402M
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2035
  • • Generic/biosimilar risk

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: BLA125781 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.